This Article Figures Only Full Text Full Text (PDF) View Online Appendix View Related Story on Cardiosmart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Hare, J. M. Search for Related Content PubMed Articles by Hare, J. M. Related Collections Related Articles

CLINICAL RESEARCH: CLINICAL TRIALS

Impact of Oxypurinol in Patients With Symptomatic Heart Failure

Results of the OPT-CHF Study

Joshua M. Hare, MD^_*,_*, Brian Mangal, MSc, Joanne Brown, BSc, Charles Fisher, Jr, MD, Ronald Freudenberger, MD, Wilson S. Colucci, MD, Douglas L. Mann, MD^||, Peter Liu, MD^¶, Michael M. Givertz, MD^#, Richard P. Schwarz, PhD^_* for the OPT-CHF Investigators

^_* The University of Miami Miller School of Medicine, Miami, Florida
Cardiome Pharma Corporation, Vancouver, British Columbia, Canada
Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Boston University, Boston, Massachusetts
^|| Baylor Heart Clinic, Houston, Texas
^¶ Toronto General Hospital, Toronto, Ontario, Canada
^# Brigham & Women's Hospital, Boston, Massachusetts.

Manuscript received October 4, 2007; revised manuscript received January 2, 2008, accepted January 15, 2008.

^_* Reprint requests and correspondence: Dr. Joshua M. Hare, Division of Cardiology, University of Miami Miller School of Medicine, 1120 NW 14th Street, Suite 1124, Miami, Florida 33136. (Email: jhare{at}med.miami.edu).

Objectives: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy.

Background: Increased XO activity may contribute to heart failure pathophysiology.

Methods: Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life.

Results: The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by 2 mg/dl (p < 0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA <9.5 mg/dl exhibited a trend towards worsening. In addition, SUA reduction to oxypurinol correlated with favorable clinical response. Within the entire oxypurinol patient cohort, those characterized as either improved or unchanged had significantly greater reductions in SUA compared with patients who worsened (–2.3 ± 2.1 mg/dl vs. –1.0 ± 1.9 mg/dl, p = 0.0006). In placebo patients, lower baseline SUA, but not change in SUA, correlated with improved clinical outcome.

Conclusions: Oxypurinol did not produce clinical improvements in unselected patients with moderate-to-severe heart failure. However, post-hoc analysis suggests that benefits occur in patients with elevated SUA in a manner correlating with the degree of SUA reduction. Serum uric acid may serve as a valuable biomarker to target XO inhibition in heart failure. (Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687 [ClinicalTrials.gov] )

Abbreviations and Acronyms   BNP = brain natriuretic peptide   CCE = composite clinical end point   CI = confidence interval   CV = cardiovascular   ITT = intent to treat   MLHF = Minnesota Living with Heart Failure   NYHA = New York Heart Association   PGHFCS = Patient Global Heart Failure Clinical Status   SUA = serum uric acid   XO = xanthine oxidase

Related Articles

The Ongoing Search for a Stratified Medicine Approach in Heart Failure

W.H. Wilson Tang
J. Am. Coll. Cardiol. 2008 51: 2310-2312. [Full Text] [PDF]

This article has been cited by other articles:

				K. Ogino, M. Kato, Y. Furuse, Y. Kinugasa, K. Ishida, S. Osaki, T. Kinugawa, O. Igawa, I. Hisatome, C. Shigemasa, et al. Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure: A Double-Blind Placebo-Controlled Crossover Preliminary Study Circ Heart Fail, January 1, 2010; 3(1): 73 - 81. [Abstract] [Full Text] [PDF]

				J. George and A. Struthers The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) Trial: A Question of Dose J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2405 - 2405. [Full Text] [PDF]

				C. Bergamini, M. Cicoira, A. Rossi, and C. Vassanelli Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure Eur J Heart Fail, May 1, 2009; 11(5): 444 - 452. [Abstract] [Full Text] [PDF]

				U. Landmesser, K. C. Wollert, and H. Drexler Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res, February 15, 2009; 81(3): 519 - 527. [Abstract] [Full Text] [PDF]

				M. Hori and K. Nishida Oxidative stress and left ventricular remodelling after myocardial infarction Cardiovasc Res, February 15, 2009; 81(3): 457 - 464. [Abstract] [Full Text] [PDF]

				S. Heymans, E. Hirsch, S. D. Anker, P. Aukrust, J.-L. Balligand, J. W. Cohen-Tervaert, H. Drexler, G. Filippatos, S. B. Felix, L. Gullestad, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, February 1, 2009; 11(2): 119 - 129. [Abstract] [Full Text] [PDF]

				M. K. Leow, C. Bueno, N. Trivedi, M. S. Parmar, J. Oh, H. Y. Won, S.-M. Kang, L. A. Hebert, B. Rovin, D. I. Feig, et al. Uric Acid and Cardiovascular Risk N. Engl. J. Med., January 29, 2009; 360(5): 538 - 541. [Full Text] [PDF]

				J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner CHAPTER 23 Heart Failure ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				H. Verdejo, D. Greig, P. Castro, H. Alcaino, L. Garcia, M. Chiong, S. Lavandero, and M. Pizarro Uric acid, xanthine oxidase and heart failure: Unresolved issues Eur J Heart Fail, December 1, 2008; 10(12): 1271 - 1272. [Full Text] [PDF]

				W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1671 - 1678. [Full Text] [PDF]

				W.H. W. Tang The ongoing search for a stratified medicine approach in heart failure. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2310 - 2312. [Full Text] [PDF]